

A brief critique by the ERG of the additional analyses and amended model provided by the manufacturer's following the introduction of a PAS.

Following amendments to the model the manufacturers report the ICERs contained in Table 1. It is suspected that these results are deterministic but this is not stated. When the ERG undertook deterministic analyses, slightly different answers were calculated; the reasons for these discrepancies are unknown.

Table 1: The ICERs estimated by the manufacturer's and the ERG

Comparison	Manufacturer's run of the model	ERG's deterministic run of the model	Deviation (Increase in ICER with ERG calculation)
B-XELOX vs XELOX	£36,494	£36,745	0.7%
B-FOLFOX-6 vs FOLFOX-6	£31,122	£31,096	-0.1%

It is noted that it is unclear where the unit costs for bevacizumab pharmacy (£46) and incremental bevacizumab administration (£63) and bevacizumab pharmacy time (0.32 hours) were derived. It is also noticed that the patient transport costs were altered (0.378 in original model and 0.3 in the amended model). The manufacturers did not specify that this need changing

When the one off APAS payment was included the deterministic ICERs calculated by the ERG fell to £29,956 and for B-XELOX vs XELOX comparison and £24,577 for the B-FOLFOX-6 vs FOLFOX-6 respectively. These values differ slightly to those presented by the manufacturer, with similar deviations to those calculated without the inclusion of the PAS.

The ERG comment that ICERs calculated from a full probabilistic model would be needed to ascertain the influence of uncertainty in changing the value estimated by the deterministic analyses.